#1 Clinical Trials Search in Europe

Study of Grass Pollen Extract and Olive Pollen Extract for Patients with Hay Fever and Asthma caused by Grass and Olive Pollen Allergies

3 1

What is this study about?

This study is being conducted to evaluate the efficacy and safety of Depigoid DUO in individuals living with allergic rhinoconjunctivitis, which is an allergic reaction affecting the nose and eyes, and potentially asthma, a condition that affects the breathing passages. These symptoms are caused by a sensitivity to grass pollen and olive pollen. The treatment involves subcutaneous injection, which means the medicine is administered via a small needle into the layer of tissue just under the skin. The study compares this treatment to a placebo.

The research aims to determine how well the immunotherapy works compared to a placebo during the periods when pollen levels are highest. Participants will receive a series of injections. During the course of the study, information regarding symptoms such as sneezing, a runny nose, itchy eyes, or breathing difficulties will be recorded. The study also considers the use of other medications, such as antihistamines or intranasal corticoids, which are sprays used to reduce inflammation in the nose.

Who Can Join the Study?

  • You must be at least 6 years old when you sign the permission forms.
  • You must have moderate or severe allergic rhinoconjunctivitis, which is a condition involving sneezing, nasal congestion, and itchy or watery eyes caused by allergies.
  • If you have asthma, a condition where your airways narrow making it hard to breathe, your asthma must be well-controlled according to medical guidelines.
  • If you have asthma, you must not have had any severe asthma exacerbations, which are sudden worsening of asthma symptoms, during the last pollen season.
  • If you have asthma, your forced expiratory volume in 1 second (FEV1), which is a measurement of how much air you can forcefully breathe out in one second, must be at least 70% of the normal amount.
  • You or your legal guardian must understand and sign the informed consent, which is a formal document explaining the study details and your rights.
  • You or your guardian must own a mobile phone that can run the specific study app and has internet access.
  • You must be able to stay in your usual home for most of the time when pollen levels are high.
  • You must be able to follow the rules and steps required by the study plan.
  • You may have preexisting stable disease, meaning a health condition that has not required new medicine or hospital visits in the 28 days before joining the study.
  • You must agree to stay in regular contact with the medical team throughout the study to ensure your safety.

Who Cannot Join the Study?

  • You have received any form of allergy immunotherapy (treatment designed to reduce allergic reactions by exposing the body to small amounts of an allergen) within the last 5 years.
  • You have any medical reason that makes it unsafe for you to receive subcutaneous allergen-specific immunotherapy (allergy shots given under the skin).
  • You have used systemic corticosteroids (strong medicines used to reduce inflammation throughout the entire body) in the 12 weeks before joining the study.
  • You have had a serious secondary reaction during a skin prick test (a test where a small amount of an allergen is placed on the skin to check for a reaction).
  • You are currently clinically unstable, meaning your health condition is changing or worsening, such as having a sudden asthma attack, a respiratory infection, a fever, or acute urticaria (a sudden outbreak of hives).
  • You have any other health condition that the doctor believes might put you at extra risk during the study.
  • You have chronic urticaria (long-lasting hives), severe dermographism (a condition where skin becomes raised or swollen after being lightly scratched), severe atopic dermatitis (a long-term skin condition causing itchiness and redness), sunburn, active psoriasis (a skin disease causing red, scaly patches) in areas being tested, or a history of hereditary angioedema (a genetic condition causing sudden swelling under the skin).
  • You have any condition that prevents you from safely receiving adrenaline (a medicine used to treat severe allergic reactions), such as certain heart diseases.
  • You are currently taking immunosuppressive treatment (medicines that lower the body’s ability to fight infections), unless it is a cream applied directly to the skin.
  • You have any other serious disease not related to your allergies or asthma, such as epilepsy (a disorder causing seizures), problems with mental or physical movement, physical malformations, kidney diseases, or having had many major surgeries.
  • You have a confirmed or suspected immunodeficiency (a condition where your immune system does not work properly).
  • You are sensitive to Alternaria alternata (a specific type of common mold).
  • You have a severe mental health disorder or any condition that prevents you from being able to cooperate with the study requirements.
  • You have a known allergy to any ingredients in vaccines other than the grass or olive extracts used in this study.
  • You have chronic lung diseases other than asthma, such as emphysema (damage to the air sacs in the lungs) or bronchiectasis (a condition where the airways become permanently widened and damaged).
  • You are a direct relative of the person conducting the study.
  • You are sensitive to dust mites (tiny organisms that live in household dust).
  • You are sensitive to epithelia (proteins found in animal skin or dander) and live with or frequently contact animals.
  • You are sensitive to other allergens that are active at the same time of year as grass and olive pollen.
  • You are currently receiving treatment with biologics (advanced medicines made from living organisms to target specific parts of the immune system).
  • Your asthma is currently uncontrolled or unstable according to medical guidelines.
  • You are a woman who is breastfeeding.
  • Women of childbearing potential who are not using reliable contraception (methods to prevent pregnancy) or who test positive for pregnancy.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Hospital Universitario De Salamanca Salamanca Spain
Hospital Clinico San Carlos Madrid Spain
Centro Hospitalar Universitario Sao Joao E.P.E. Porto Portugal
Hospital Universitario De Navarra Pamplona Spain
Unidade Local De Saúde De Santa Maria, E.P.E. Lisbon Portugal

Other Sites

Site Name City Country Status
Hospital Universitario Puerta De Hierro De Majadahonda Majadahonda Spain
Hospital Universitario 12 De Octubre Madrid Spain
Hospital Universitario Infanta Leonor Madrid Spain
Hospital Universitario Virgen De Las Nieves Granada Spain
Hospital Universitario De Fuenlabrada Fuenlabrada Spain
Hospital General Universitario De Albacete Albacete Spain
ULS De Castelo Branco E.P.E. Castelo Branco Portugal
Hospital Particular do Algarve S.A. Faro Portugal
Consorci Sanitari De Terrassa Terrassa Spain
Hospital Universitario Del Sureste – Empresa Publica Hosptial Del Sureste Arganda Del Rey Spain
Hospital Universitario Infanta Sofía San Sebastian De Los Reyes Spain
University Clinical Hospital Virgen De La Arrixaca Murcia Spain
Hospital General Universitario De Valencia Valencia Spain
Hospital General Universitario De Castellon Castello De La Plana Spain
Hospital Universitario General De Villalba Madrid Spain
Hospital Nuestra Senora De Sonsoles Avila Spain
Hospital Cuf Tejo S.A. Lisbon Portugal
Unidade Local De Saude Do Alto Ave E.P.E. Guimaraes Portugal
Hszkmhni Uvgeghcbcawgl Ds Lv Prshjhbw Madrid Spain
Hjxwqokk Usjekvjyxyouf Dz Bsgbbrc Badajoz Spain
Cmpefcwv Hkcsiasccvm Df Vqy Vic Spain
Fvmzfjcen Pfee Lq Iyjurpmzypjaj Bhljofama Duk Hhibekqs Uukkggflrkryy Le Pmw Madrid Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Portugal Portugal
Not yet recruiting
20.07.2026
Spain Spain
Not yet recruiting
20.07.2026

Trial locations

Investigated drugs:

Depigoid DUO Grass-Mix/Olea is an allergy treatment given by injection under the skin. It contains processed extracts from various types of grass pollen and olive pollen, designed to help the body become less sensitive to these specific allergens.

Investigated diseases:

Allergic rhinoconjunctivitis with or without asthma due to clinically relevant sensitisation to grass and olive pollen – This condition occurs when the immune system overreacts to specific proteins found in grass and olive pollen. It causes inflammation of the nasal passages and the lining of the eyes. Common symptoms include sneezing, a runny nose, nasal congestion, itchy eyes, and tearing. In some individuals, this allergic response can also involve the airways, leading to asthma symptoms. The condition typically progresses or worsens during periods when pollen levels are high in the air.

Trial ID:
2025-521709-42-00
Protocol code:
060018-PG-PSC-217
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study of bilastine for effectiveness, safety and quality of life in children aged 6 to 12 years with allergic rhinoconjunctivitis

    Recruiting

    3 1 1 1
    Investigated drugs:
    Italy Poland Spain

  • Testing sublingual immunotherapy with dermatophagoides pteronyssinus extract for adults with moderate to severe house dust mite allergy

    Recruiting

    4 1
    Investigated drugs:
    Germany Spain